{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:20:59Z","timestamp":1763018459796,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41409-022-01588-8","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T09:03:17Z","timestamp":1643878997000},"page":"664-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Defibrotide-treated patients with anicteric or icteric veno-occlusive disease\/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-1127","authenticated-orcid":false,"given":"Thomas","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Jubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Hanvesakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-3197","authenticated-orcid":false,"given":"Katia","family":"Perruccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"1588_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157\u201368. https:\/\/doi.org\/10.1016\/j.bbmt.2009.08.024","journal-title":"Biol Blood Marrow Transplant"},{"key":"1588_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","volume":"11","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Barbato F, Ravaioli F, Sessa M, Defrancesco I, Arpinati M, et al. Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489 https:\/\/doi.org\/10.3389\/fimmu.2020.00489","journal-title":"Front Immunol"},{"key":"1588_CR3","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.bbmt.2020.03.011","volume":"26","author":"S Corbacioglu","year":"2020","unstructured":"Corbacioglu S, Kernan NA, Pagliuca A, Ryan RJ, Tappe W, Richardson PG. Incidence of anicteric veno-occlusive disease\/sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients. Biol Blood Marrow Transplant. 2020;26:1342\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.011","journal-title":"Biol Blood Marrow Transplant"},{"key":"1588_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2018;53:138\u201345. https:\/\/doi.org\/10.1038\/bmt.2017.161","journal-title":"Bone Marrow Transplant"},{"key":"1588_CR5","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/S2352-3026(19)30201-7","volume":"7","author":"KM Mahadeo","year":"2020","unstructured":"Mahadeo KM, Bajwa R, Abdel-Azim H, Lehmann LE, Duncan C, Zantek N, et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2020;7:e61\u2013e72. https:\/\/doi.org\/10.1016\/S2352-3026(19)30201-7","journal-title":"Lancet Haematol"},{"key":"1588_CR6","doi-asserted-by":"publisher","unstructured":"Cairo MS, Cooke KR, Lazarus HM, Chao N. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation. Br J Haematol. 2020;190;822\u201336. https:\/\/doi.org\/10.1111\/bjh.16557","DOI":"10.1111\/bjh.16557"},{"key":"1588_CR7","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(11)61938-7","journal-title":"Lancet"},{"key":"1588_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2016;51:403\u20139. https:\/\/doi.org\/10.1038\/bmt.2015.283","journal-title":"Bone Marrow Transplant"},{"key":"1588_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.16621","volume":"190","author":"GC Hildebrandt","year":"2020","unstructured":"Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol. 2020;190:508\u201319. https:\/\/doi.org\/10.1111\/bjh.16621","journal-title":"Br J Haematol"},{"key":"1588_CR10","unstructured":"Defitelio (defibrotide sodium) injection. Summary of product characteristics. Jazz Pharmaceuticals Ireland, Limited; 2019."},{"key":"1588_CR11","unstructured":"Defitelio (defibrotide sodium) injection. Prescribing information. Jazz Pharmaceuticals, Inc.; 2016."},{"key":"1588_CR12","doi-asserted-by":"publisher","unstructured":"Mohty M, Battista ML, Blaise D, Calore E, Cesaro S, Maximova N, et al. A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease\/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study. Bone Marrow Transplant. 2021;56:2454\u201363. https:\/\/doi.org\/10.1038\/s41409-021-01265-2","DOI":"10.1038\/s41409-021-01265-2"},{"key":"1588_CR13","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","volume":"22","author":"S Corbacioglu","year":"2016","unstructured":"Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program. Biol Blood Marrow Transplant. 2016;22:1874\u201382. https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"1588_CR14","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15267","volume":"181","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Br J Haematol. 2018;181:816\u201327. https:\/\/doi.org\/10.1111\/bjh.15267","journal-title":"Br J Haematol"},{"key":"1588_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41409-020-00998-w","volume":"56","author":"D Ragoonanan","year":"2021","unstructured":"Ragoonanan D, Khazal SJ, Wang J, Payne A, Kohorst M, Harden A, et al. Improved detection of sinusoidal obstructive syndrome using pediatric\u2013AYA diagnostic criteria and severity grading. Bone Marrow Transplant. 2021;56:175\u201384. https:\/\/doi.org\/10.1038\/s41409-020-00998-w","journal-title":"Bone Marrow Transplant"},{"key":"1588_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","volume":"33","author":"S Corbacioglu","year":"2004","unstructured":"Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004;33:189\u201395. https:\/\/doi.org\/10.1038\/sj.bmt.1704329","journal-title":"Bone Marrow Transplant"},{"key":"1588_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906\u201312. https:\/\/doi.org\/10.1038\/bmt.2016.130","journal-title":"Bone Marrow Transplant"},{"key":"1588_CR18","doi-asserted-by":"publisher","first-page":"e27269","DOI":"10.1002\/pbc.27269","volume":"65","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Richardson PG, Smith AR, Triplett BM, Antin JH, Lehmann L, et al. Defibrotide for the treatment of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer. 2018;65:e27269 https:\/\/doi.org\/10.1002\/pbc.27269","journal-title":"Pediatr Blood Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01588-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01588-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01588-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T14:06:05Z","timestamp":1649426765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01588-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01588-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"26 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM has received honoraria and research funding from Jazz Pharmaceuticals. TC and SL have received honoraria from Jazz Pharmaceuticals. CJ has received research funding from Jazz Pharmaceuticals. RJR is a former employee of and holds stock in Jazz Pharmaceuticals. RH is an employee of and holds stock and\/or stock options in Jazz Pharmaceuticals. KP has no conflicts to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}